Hans van den Heuvel

REFERENCES 1. Queenan JT. Management of High‐Risk Pregnancy: John Wiley And Sons Ltd, 2012 2. NICE Guideline CG107 Hypertension in pregnancy: diagnosis and management. 2010 (updated in 2011). (accessed 15-11-2018). 3. RCOG. Green-top Guideline No.31 - The Investigation and Management of the Small–for– Gestational–Age Fetus. 2014. (accessed 15-11-2018). 4. NICE Guideline NG25 Preterm labour and birth. 2015. (accessed 15-11-2018). 5. Gourounti K, Karpathiotaki N, Vaslamatzis G. Psychosocial stress in high risk pregnancy. International Archives of Medicine Section: Psychiatry and Mental Health. 2015;8(95). 6. Huynh, L., McCoy, M., Law, A. et al. Systematic Literature Review of the Costs of Pregnancy in the US PharmacoEconomics (2013) 31: 1005. 7. World Health Organization. mHealth: NewHorizons for Health ThroughMobile Technologies. Global Observatory for eHealth Series, Volume 3. Geneva, Switzerland: WHO; 2011. 8. Dorsey ER, Topol EJ. State of Telehealth. N Engl J Med 2016 Jul 14;375(2):154-161. 9. van den Heuvel JFM, Groenhof TK, Veerbeek JHW, van Solinge WW, Lely AT, Franx A, Bekker MN ; eHealth as the Next-Generation Perinatal Care: An Overview of the Literature ; J Med Internet Res 2018;20(6):e202 10. Y. Chung, A. de Greeff, A. Shennan, Validation and compliance of a home monitoring device in pregnancy: Microlife WatchBP home, Hypertens. Pregnancy 28 (3) (2009) 348–359. 11. Boatin AA, Wylie B, Goldfarb I, Azevedo R, Pittel E, Ng C, et al. (2015)Wireless Fetal Heart Rate Monitoring in Inpatient Full-Term Pregnant Women: Testing Functionality and Acceptability. PLoS ONE 10 (1): e0117043. 12. Buysse H, De Moor MG, Van Maele G, Baert E, Thienpont G, Temmerman M. Cost-effectiveness of telemonitoring for high-risk pregnant women. Int J Med Inform 2008 Jul;77(7):470-476. 13. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014;4(2):97-104. 14. M. Versteegh M, M. Vermeulen K, M. A. A. Evers S, de Wit GA, Prenger R, A. Stolk E. Dutch tariff for the five-level version of EQ-5D. Value in Health. 2016. 15. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the spielberger state-trait anxiety inventory (STAI). Br J Clin Psychol. 1992;31 ( Pt 3)(Pt 3):301- 306. 16. Bergink V, Kooistra L, Lambregtse-van den Berg MP, et al. Validation of the edinburgh depression scale during pregnancy. J Psychosom Res. 2011;70(4):385-389. 17. van der HamDP, van der Heyden JL, Opmeer BC, et al. Management of late-pretermpremature rupture of membranes: The PPROMEXIL-2 trial. Am J Obstet Gynecol. 2012;207(4):276.e1- 276.10. 18. Boers KE, Vijgen SM, Bijlenga D, et al. Induction versus expectant monitoring for intrauterine growth restriction at term: Randomised equivalence trial (DIGITAT). BMJ. 2010;341:c7087. 19. Broekhuijsen K, van Baaren GJ, van Pampus MG, et al. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): An open-label, randomised controlled trial. Lancet. 2015;385(9986):2492- 2501. CHAPTER 10 174